ArticleClinical and translational gastroenterology2020

Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study.

Brigida Barberio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.